EPCR Promotes Breast Cancer Progression by Altering SPOCK1/testican 1-mediated 3D Growth

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2017 Jan 21

PMID 28103946

Citations 15

Authors

Naiara Perurena

Carolina Zandueta

Susana Martinez-Canarias

Haritz Moreno

Silvestre Vicent

Ana S Almeida

Elisabet Guruceaga

Roger R Gomis

Marta Santisteban

Mikala Egeblad

Jose Hermida

Fernando Lecanda

Affiliations

Soon will be listed here.

Abstract

Background: Activated protein C/endothelial protein C receptor (APC/EPCR) axis is physiologically involved in anticoagulant and cytoprotective activities in endothelial cells. Emerging evidence indicates that EPCR also plays a role in breast stemness and human tumorigenesis. Yet, its contribution to breast cancer progression and metastasis has not been elucidated.

Methods: Transcriptomic status of EPCR was examined in a cohort of 286 breast cancer patients. Cell growth kinetics was evaluated in control and EPCR and SPARC/osteonectin, Cwcv, and kazal-like domains proteoglycan (SPOCK1/testican 1) silenced breast cancer cells in 2D, 3D, and in co-culture conditions. Orthotopic tumor growth and lung and osseous metastases were evaluated in several human and murine xenograft breast cancer models. Tumor-stroma interactions were further studied in vivo by immunohistochemistry and flow cytometry. An EPCR-induced gene signature was identified by microarray analysis.

Results: Analysis of a cohort of breast cancer patients revealed an association of high EPCR levels with adverse clinical outcome. Interestingly, EPCR knockdown did not affect cell growth kinetics in 2D but significantly reduced cell growth in 3D cultures. Using several human and murine xenograft breast cancer models, we showed that EPCR silencing reduced primary tumor growth and secondary outgrowths at metastatic sites, including the skeleton and the lungs. Interestingly, these effects were independent of APC ligand stimulation in vitro and in vivo. Transcriptomic analysis of EPCR-silenced tumors unveiled an effect mediated by matricellular secreted proteoglycan SPOCK1/testican 1. Interestingly, SPOCK1 silencing suppressed in vitro 3D growth. Moreover, SPOCK1 ablation severely decreased orthotopic tumor growth and reduced bone metastatic osteolytic tumors. High SPOCK1 levels were also associated with poor clinical outcome in a subset breast cancer patients. Our results suggest that EPCR through SPOCK1 confers a cell growth advantage in 3D promoting breast tumorigenesis and metastasis.

Conclusions: EPCR represents a clinically relevant factor associated with poor outcome and a novel vulnerability to develop combination therapies for breast cancer patients.

Citing Articles

SPOCK: Master regulator of malignant tumors (Review).

Xiao M, Xue J, Jin E Mol Med Rep. 2024; 30(6).

PMID: 39392048 PMC: 11487499. DOI: 10.3892/mmr.2024.13355.

Stromal cells in the tumor microenvironment: accomplices of tumor progression?.

Zhao Y, Shen M, Wu L, Yang H, Yao Y, Yang Q Cell Death Dis. 2023; 14(9):587.

PMID: 37666813 PMC: 10477351. DOI: 10.1038/s41419-023-06110-6.

New insights into vitamin K biology with relevance to cancer.

Welsh J, Bak M, Narvaez C Trends Mol Med. 2022; 28(10):864-881.

PMID: 36028390 PMC: 9509427. DOI: 10.1016/j.molmed.2022.07.002.

Multiomic analysis of the function of across cancers: an integrated bioinformatics approach.

Han J, Rong Y, Gao X J Int Med Res. 2021; 49(6):300060520962659.

PMID: 34156309 PMC: 8236807. DOI: 10.1177/0300060520962659.

Proteoglycans as Mediators of Cancer Tissue Mechanics.

Barkovskaya A, Buffone Jr A, Zidek M, Weaver V Front Cell Dev Biol. 2020; 8:569377.

PMID: 33330449 PMC: 7734320. DOI: 10.3389/fcell.2020.569377.

References

Chen L, Chan T, Liu M, Kong K, Qiu J, Li Y . SPOCK1 is regulated by CHD1L and blocks apoptosis and promotes HCC cell invasiveness and metastasis in mice. Gastroenterology. 2012; 144(1):179-191.e4. DOI: 10.1053/j.gastro.2012.09.042. View

Heng W, Mu C, Chen C, Huang J, Wang Z . Endothelial cell protein C receptor (EPCR) is expressed by lung carcinoma and correlated with clinical parameters. Clin Lab. 2013; 59(3-4):375-80. DOI: 10.7754/clin.lab.2012.120214. View

Keshava S, Kothari H, Rao L, Pendurthi U . Influence of endothelial cell protein C receptor on breast cancer development. J Thromb Haemost. 2013; 11(11):2062-5. PMC: 3845670. DOI: 10.1111/jth.12402. View

Shu Y, Weng H, Ye Y, Hu Y, Bao R, Cao Y . SPOCK1 as a potential cancer prognostic marker promotes the proliferation and metastasis of gallbladder cancer cells by activating the PI3K/AKT pathway. Mol Cancer. 2015; 14:12. PMC: 4320842. DOI: 10.1186/s12943-014-0276-y. View

Miao L, Wang Y, Xia H, Yao C, Cai H, Song Y . SPOCK1 is a novel transforming growth factor-β target gene that regulates lung cancer cell epithelial-mesenchymal transition. Biochem Biophys Res Commun. 2013; 440(4):792-7. DOI: 10.1016/j.bbrc.2013.10.024. View

Knutson K, Lu H, Stone B, Reiman J, Behrens M, Prosperi C . Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol. 2006; 177(3):1526-33. DOI: 10.4049/jimmunol.177.3.1526. View

Valencia K, Luis-Ravelo D, Bovy N, Anton I, Martinez-Canarias S, Zandueta C . miRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization. Mol Oncol. 2014; 8(3):689-703. PMC: 5528646. DOI: 10.1016/j.molonc.2014.01.012. View

Keshava S, Sahoo S, Tucker T, Idell S, Rao L, Pendurthi U . Endothelial cell protein C receptor opposes mesothelioma growth driven by tissue factor. Cancer Res. 2013; 73(13):3963-73. PMC: 3702650. DOI: 10.1158/0008-5472.CAN-12-1690. View

Turner L, Lavstsen T, Berger S, Wang C, Petersen J, Avril M . Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013; 498(7455):502-5. PMC: 3870021. DOI: 10.1038/nature12216. View

10.

Ducros E, Mirshahi S, Azzazene D, Camilleri-Broet S, Mery E, Al Farsi H . Endothelial protein C receptor expressed by ovarian cancer cells as a possible biomarker of cancer onset. Int J Oncol. 2012; 41(2):433-40. PMC: 3582880. DOI: 10.3892/ijo.2012.1492. View

11.

Anton I, Molina E, Luis-Ravelo D, Zandueta C, Valencia K, Ormazabal C . Receptor of activated protein C promotes metastasis and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med. 2012; 186(1):96-105. PMC: 5448647. DOI: 10.1164/rccm.201110-1826OC. View

12.

Rao L, Esmon C, Pendurthi U . Endothelial cell protein C receptor: a multiliganded and multifunctional receptor. Blood. 2014; 124(10):1553-62. PMC: 4155268. DOI: 10.1182/blood-2014-05-578328. View

13.

Egeblad M, Nakasone E, Werb Z . Tumors as organs: complex tissues that interface with the entire organism. Dev Cell. 2010; 18(6):884-901. PMC: 2905377. DOI: 10.1016/j.devcel.2010.05.012. View

14.

Kang Y, Siegel P, Shu W, Drobnjak M, Kakonen S, Cordon-Cardo C . A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003; 3(6):537-49. DOI: 10.1016/s1535-6108(03)00132-6. View

15.

Burleigh A, McKinney S, Brimhall J, Yap D, Eirew P, Poon S . A co-culture genome-wide RNAi screen with mammary epithelial cells reveals transmembrane signals required for growth and differentiation. Breast Cancer Res. 2015; 17:4. PMC: 4322558. DOI: 10.1186/s13058-014-0510-y. View

16.

Scheffer G, Flens M, Hageman S, Izquierdo M, Shoemaker R, Scheper R . Expression of the vascular endothelial cell protein C receptor in epithelial tumour cells. Eur J Cancer. 2002; 38(11):1535-42. DOI: 10.1016/s0959-8049(02)00108-9. View

17.

Willcox C, Pitard V, Netzer S, Couzi L, Salim M, Silberzahn T . Cytomegalovirus and tumor stress surveillance by binding of a human γδ T cell antigen receptor to endothelial protein C receptor. Nat Immunol. 2012; 13(9):872-9. DOI: 10.1038/ni.2394. View

18.

Wang D, Cai C, Dong X, Yu Q, Zhang X, Yang L . Identification of multipotent mammary stem cells by protein C receptor expression. Nature. 2014; 517(7532):81-4. DOI: 10.1038/nature13851. View

19.

Beaulieu L, Church F . Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1. Exp Cell Res. 2007; 313(4):677-87. PMC: 4055951. DOI: 10.1016/j.yexcr.2006.11.019. View

20.

Gonzalez I, Vicent S, de Alava E, Lecanda F . EWS/FLI-1 oncoprotein subtypes impose different requirements for transformation and metastatic activity in a murine model. J Mol Med (Berl). 2007; 85(9):1015-29. DOI: 10.1007/s00109-007-0202-5. View